{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-048597","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.102304+00:00","generated_at":"2026-05-20T06:26:38.789046+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Estrella Immunopharma doses first patient in STARLIGHT-1 second cohort for EB103 in NHL","bullets":["First patient dosed in second cohort of Phase I/II STARLIGHT-1 trial evaluating EB103 at higher dose.","No dose-limiting toxicities or treatment-related serious adverse events observed in first cohort.","Complete response reported in first cohort; trial targets advanced B-cell non-Hodgkin's lymphomas.","CEO Cheng Liu highlights potential for HIV-associated and CNS lymphoma patients currently excluded from CAR-T."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-048597","json":"https://secwatch.observer/filing/0001213900-25-048597.json","markdown":"https://secwatch.observer/filing/0001213900-25-048597.md","text":"https://secwatch.observer/filing/0001213900-25-048597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025048597/0001213900-25-048597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025048597/ea0243703-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T06:26:38.789046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}